Abatacept for Crohn's disease and ulcerative colitis.

BACKGROUND & AIMS The efficacy of abatacept, a selective costimulation modulator, in Crohn's disease (CD) and ulcerative colitis (UC) is unknown. METHODS Four placebo-controlled trials evaluated the efficacy and safety of abatacept as induction (IP) and maintenance (MP) therapy in adults with active, moderate-to-severe CD (CD-IP; CD-MP) and UC (UC-IP1; UC-MP). In CD-IP and UC-IP1, 451 patients with CD and 490 patients with UC were randomized to abatacept 30, 10, or 3 mg/kg (according to body weight) or placebo, and dosed at weeks 0, 2, 4, and 8. In MP, 90 patients with CD and 131 patients with UC who responded to abatacept at week 12 in the induction trials were randomized to abatacept 10 mg/kg or placebo every 4 weeks through week 52. RESULTS In CD-IP, 17.2%, 10.2%, and 15.5% of patients receiving abatacept 30, 10, and 3 mg/kg achieved a clinical response at weeks 8 and 12, vs 14.4% receiving placebo (P = .611, P = .311, and P = .812, respectively). In UC-IP1, 21.4%, 19.0%, and 20.3% of patients receiving abatacept 30, 10, and 3 mg/kg achieved a clinical response at week 12, vs 29.5% receiving placebo (P = .124, P = .043, and P = .158, respectively). In CD-MP, 23.8% vs 11.1% of abatacept vs placebo patients were in remission at week 52. In UC-MP, 12.5% vs 14.1% of patients receiving abatacept vs placebo were in remission at week 52. Safety generally was comparable between groups. CONCLUSIONS The studies showed that abatacept is not efficacious for the treatment of moderate-to-severe CD or UC.

[1]  D. Littman,et al.  Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. , 2011, Gastroenterology.

[2]  S. Targan,et al.  Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis , 2010, Gut.

[3]  B. Sands,et al.  389 A Randomized, Double-Blind, Placebo-Controlled Trial of Basiliximab with Concomitant Corticosteroids in Steroid-Refractory Ulcerative Colitis , 2009 .

[4]  S. Barry,et al.  Foxp3+ Regulatory T Cells, Th17 Effector Cells, and Cytokine Environment in Inflammatory Bowel Disease , 2009, Journal of Clinical Immunology.

[5]  A. Martini,et al.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2008, The Lancet.

[6]  L. Peyrin-Biroulet,et al.  Crohn's disease: beyond antagonists of tumour necrosis factor , 2008, The Lancet.

[7]  Å. Danielsson,et al.  Basal lymphoid aggregates in ulcerative colitis colon: a site for regulatory T cell action , 2008, Clinical and experimental immunology.

[8]  S. Carding,et al.  Inflammatory bowel disease: cause and immunobiology , 2007, The Lancet.

[9]  W. Sandborn,et al.  Inflammatory bowel disease: clinical aspects and established and evolving therapies , 2007, The Lancet.

[10]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[11]  K. Papadakis,et al.  Expression and functional characterization of FOXP3+CD4+ regulatory T cells in ulcerative colitis , 2007, Inflammatory bowel diseases.

[12]  S. Targan,et al.  Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial , 2006, Gut.

[13]  T. Matsui,et al.  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis , 2006, Gut.

[14]  H. Genant,et al.  Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis , 2006, Annals of Internal Medicine.

[15]  M. Dougados,et al.  Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[16]  Tetsuya Nakamura,et al.  CD4+CD25bright T Cells in Human Intestinal Lamina Propria as Regulatory Cells1 , 2004, The Journal of Immunology.

[17]  P. Emery.  The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis , 2003, Expert opinion on investigational drugs.

[18]  W. Sandborn,et al.  Cyclosporin for refractory ulcerative colitis , 2003, Gut.

[19]  Andrea Iaboni,et al.  The interaction properties of costimulatory molecules revisited. , 2002, Immunity.

[20]  D. Coppola,et al.  Inhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4+ T cells correlates with suppression of psoriasis and colitis. , 2002, International immunopharmacology.

[21]  P. Rutgeerts,et al.  A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. , 2002, Gastroenterology.

[22]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[23]  Fiona Powrie,et al.  Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation , 2000, The Journal of experimental medicine.

[24]  J. Bluestone,et al.  CD28/B7 system of T cell costimulation. , 1996, Annual review of immunology.

[25]  P. Linsley,et al.  CTLA-4 is a second receptor for the B cell activation antigen B7 , 1991, The Journal of experimental medicine.

[26]  W. Tremaine,et al.  Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.

[27]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.